Rapport Therapeutics RAPP 深 沪
等待开盘 05-20 09:30:00 美东时间
34.475
-0.705
-2.00%
华盛通- 最 高35.79
- 今 开35.47
- 成交量 16.94万股
- 最 低 33.815
- 昨 收 35.18
- 总市值 16.49亿
- 52周最高 42.2685
- 市盈率 静 --
- 换手率 0.35%
- 52周最低 8.195
- 委 比 93.04%
- 总股本 4782.69万
- 历史最高 42.2685
- 量 比 0.97
- 振 幅 5.61%
- 历史最低 6.43
- 每 手 1
- 风险率 8.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
BTIG Reiterates Buy on Rapport Therapeutics, Maintains $53 Price Target
BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $53 price target.
05-08 18:34
Rapport Therapeutics, Inc. (RAPP) Gets a Buy from JonesTrading
JonesTrading analyst Justin Walsh reiterated a Buy rating on Rapport Therapeuti...
05-08 04:36
Rapport Therapeutics Q1 EPS $(0.42) Beats $(0.65) Estimate, Sales $20.000M Beat $8.571M Estimate
Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.65) by 35.38 percent. This is a 38.24 percent increase over losses of $(0.68) per share
05-07 20:40
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
Rapport Therapeutics reported positive Phase 2a follow-up data for RAP-219 in focal onset seizures (FOS), showing a 90% median reduction in clinical seizures over baseline. The Phase 3 program for FOS remains on track to begin in Q2 2026. Bipolar mania Phase 2 trial results are now expected in Q4 2026, ahead of previous guidance. RAP-219's long-acting injectable formulation and other pipeline programs are advancing. The company entered a collabor...
05-07 11:00
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
Rapport Therapeutics will present Phase 2a results for RAP-219, a potential first-in-class TARPγ8-specific AMPA receptor negative allosteric modulator, at the 2026 AAN Annual Meeting. The presentation will highlight efficacy and tolerability data in patients with focal onset seizures, with potential applications in epilepsy, bipolar disorder, and chronic pain. RAP-219 targets brain regions linked to seizures while minimizing hindbrain activity, o...
04-01 11:00
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
Rapport Therapeutics Q4 EPS $(0.72) Misses $(0.69) Estimate
Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.69) by 5.11 percent. This is a 26.32 percent decrease over losses of $(0.57) per share
03-10 19:23
BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers, Live Nation, NovaBridge
BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers, Live Nation, NovaBridge Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 20 (Reuters) - U.S. stock index futures tumbled more than
03-09 21:29
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China
Rapport Therapeutics and Tenacia Biotechnology have entered a collaboration granting Tenacia exclusive rights to develop and commercialize RAP-219 in Greater China. RAP-219, a potential first-in-class TARPγ8-specific AMPA receptor negative allosteric modulator, is being developed for focal onset seizures and bipolar mania. Rapport will receive a $20 million upfront payment, up to $308 million in milestones, and tiered royalties. Tenacia's experti...
03-09 11:00
